Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has a history of ragweed allergic rhinitis (hayfever) during at least the last 2 consecutive seasons that has required treatment with antihistamines, decongestants and/or nasal steroids, but where symptom relief has been incomplete~* Is willing to stay in their ragweed area during the historical peak period of the local ragweed season, and willing to travel for no more than 2 weeks (cumulative time) outside of their ragweed area during the entire season~Exclusion Criteria:~* Has had any hospital admissions for asthma~* Has smoked within the past year, or has a ≥10-pack per year smoking history~* Has had any previous immunotherapy with ragweed pollen extract, or was in a previous clinical trial with TOLAMBA™~* Has used Xolair within the past 12 months~* Has a history of anaphylaxis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): TOLAMBA™ dose-intense regimen
- 2 (Type: EXPERIMENTAL): TOLAMBA™ lower-dose regimen
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).